Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas C Shea

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
The Lancet. Haematology|March 31, 2024
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30<sup>+</sup> lymphoma: a phase 1 studyNatalie S Grover, George Hucks, Marcie L Riches, et al.
Leukemia & Lymphoma|January 11, 2019
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysisZeina Al-Mansour, Hongli Li, James R Cook, et al.
The New England Journal of Medicine|November 1, 2013
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphomaPatrick J Stiff, Joseph M Unger, James R Cook, et al.
Blood|January 1, 2005
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesRobert Z Orlowski, Peter M Voorhees, Reynaldo A Garcia, et al.
Cancer Immunology Research|January 11, 2015
Peptide/MHC tetramer-based sorting of CD8⁺ T cells to a leukemia antigen yields clonotypes drawn nonspecifically from an underlying restricted repertoireSally A Hunsucker, Colleen S McGary, Benjamin G Vincent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2020
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin LymphomaCarlos A Ramos, Natalie S Grover, Anne W Beaven, et al.
Leukemia Research|May 4, 2004
A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapyFrancis J Giles, Roberto Rodriguez, Daniel Weisdorf, et al.
International Journal of Molecular Sciences|February 5, 2020
Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant PatientsJing Zhu, Tejendra Patel, Jordan A Miller, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 8, 2010
A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTRHillard M Lazarus, Mei-Jie Zhang, Jeanette Carreras, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphomaTimothy S Fenske, Parameswaran N Hari, Jeanette Carreras, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
The Lancet. Haematology|March 31, 2024
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30<sup>+</sup> lymphoma: a phase 1 studyNatalie S Grover, George Hucks, Marcie L Riches, et al.
Leukemia & Lymphoma|January 11, 2019
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysisZeina Al-Mansour, Hongli Li, James R Cook, et al.
The New England Journal of Medicine|November 1, 2013
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphomaPatrick J Stiff, Joseph M Unger, James R Cook, et al.
Blood|January 1, 2005
Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignanciesRobert Z Orlowski, Peter M Voorhees, Reynaldo A Garcia, et al.
Cancer Immunology Research|January 11, 2015
Peptide/MHC tetramer-based sorting of CD8⁺ T cells to a leukemia antigen yields clonotypes drawn nonspecifically from an underlying restricted repertoireSally A Hunsucker, Colleen S McGary, Benjamin G Vincent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2020
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin LymphomaCarlos A Ramos, Natalie S Grover, Anne W Beaven, et al.
Leukemia Research|May 4, 2004
A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapyFrancis J Giles, Roberto Rodriguez, Daniel Weisdorf, et al.
International Journal of Molecular Sciences|February 5, 2020
Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant PatientsJing Zhu, Tejendra Patel, Jordan A Miller, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 8, 2010
A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTRHillard M Lazarus, Mei-Jie Zhang, Jeanette Carreras, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 14, 2009
Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphomaTimothy S Fenske, Parameswaran N Hari, Jeanette Carreras, et al.
Pageof 8